Trial
NCT07283848
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Massachusetts General Hospital
Collaborators
Arcus Biosciences, Inc.; Gateway for Cancer Research
Condition
Adenocarcinoma Stomach
Intervention
Zimberelimab
Why stopped
The pharmaceutical company is not moving forward with this intervention due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-26